Crinetics
Pharmaceuticals

Selective SST5 Agonists for the Treatment of Hyperinsulinism

Congenital Hyperinsulinism Family Conference

Philadelphia, Pennsylvania

September 2019



Crinetics: Who We Are and What We Do

OUR VISION

To build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives

Our CHI hypothesis: an oral, selective-sst5 drug is the optimal strategy for treating all HI patients



sst5 Agonists: Positive results from preclinical studies

Rescue of hypoglycemia in rats induced by treatment with sulfonylurea glyburide



- Rescue insulin induced hypoglycemia
- Suppress insulin secretion
- Maintain glucagon levels

In an OGTT, CRNX agonist suppressed insulin…



…while maintaining glucagon levels



Our CHI Goals

- Deliver a new medicinal option for CHI clinicians and families
  - Oral pill (solution for infants)
    - *No Injections!*
  - Effective for most *(all?)* CHI mutations
  - Lower insulin levels
  - Prevent hypoglycemia
- Start human clinical trials asap!

sbetz@crinetics.com

Crinetics Pharmaceuticals